CARESIDE INC Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (23)

View All

Latest Posts

About This Stock More About This Stock
Week In Review: Inventis Closes $70 Million Financing To Develop 30 Novel Therapeutics
Article By: ChinaBio® Today
Saturday, March 16, 2019 4:22 PM EDT
InventisBio of Shanghai closed a $70 million Series C financing led by Advantech Capital and CMBI, followed by Pudong Innotek. Founded in 2013, InventisBio focuses on discovering and developing novel therapeutics for cancer and metabolic diseases.
In this article: CASI, NTRA
Read
Week In Review: Grifols Pays $1.9 Billion For 26% Stake In Shanghai RAAS
Article By: ChinaBio® Today
Saturday, March 9, 2019 4:13 PM EDT
Grifols, a Barcelona maker of plasma-based medicines, acquired a 26% stake in Chinese blood plasma company Shanghai RAASfor $1.9 billion in a non-cash deal. Grifols will exchange a 45% ownership in Grifols Diagnostic Solutions for the RAAS stake.
In this article: CASI, BGNE, GRFS, NVO
Read
Week In Review: China Pharmas Announce Deals Worth $1.5 Billion
Article By: ChinaBio® Today
Saturday, December 8, 2018 4:21 PM EDT
WuXi AppTec, China's largest CRO/CMO, completed a $1 billion IPO on the Hong Kong markets, pricing the offering in the middle of the expected range (see story). In May, WuXi became a public company by completing a $328 million IPO in Shanghai.
In this article: RVNC, VBIV, CASI, SPPI
Read
Week In Review: Alphamab Closes $100 Million Series A For Oncology Candidates
Article By: ChinaBio® Today
Saturday, November 24, 2018 4:09 PM EDT
Alphamab Oncology, a clinical-stage Suzhou biopharma, completed a Series A funding with over $100 million in capital. Earlier this year, Alphamab Oncology was spun out of Suzhou Alphamab with seven oncology assets and related technology platforms.
In this article: LLY, CASI, BIIB, GILD
Read
Week In Review: Innovent Completes $421 Million Hong Kong IPO; Will Start Trading Next Week
Article By: ChinaBio® Today
Saturday, October 27, 2018 5:08 PM EDT
Innovent Biologics has priced its Hong Kong IPO to raise $421 million. The successful IPO shows investors are still interested in young China biopharmas. he IPO values Innovent at $2 billion; its shares will begin trading on October 31.
In this article: CASI, ZLAB
Read
All Posts

PARTNER HEADLINES

Latest Tweets for $CASI

No tweets yet!